Use of Platelet-rich Plasma for Vulvovaginal Autoimmune Conditions Like Lichen Sclerosus

Fariba Behnia-Willison, MBBS, MIS, FRANZCOG†‡ Nina Reza Pour, MD, DRANZCOG, FRANZCOG Trainee§ Behrang Mohamadi* Nadia Willison¶ Madeleine Rock|| Ian W. Holten, MBBS, MD, FRACS, FRCS (Plas) Lon** Robert O’Shea, MBBS, FRANZCOG, FRCOG†‡ Joseph Miller, BS*

Background: Lichen sclerosus (LS) is a chronic autoimmune inflammatory dermatosis characterized by a lymphocytic response that has a predilection for the genital skin in both sexes and an association with several other autoimmune diseases.1 Women are 6 to 10 times more often affected than men.2 LS may involve complications of erosions, atrophy, and scarring as a result of inflammation and altered fibroblast function, leading to fibrosis of the upper dermis. There can also be purpura, hyperpigmentation, fissures, and edema.3 LS mainly affects the anogenital area of the skin, in more than a 5:1 ratio when compared with extragenital skin.4

LS is relatively common although the true incidence is unknown and likely underestimated, in part, due to the distribution of patients among different clinical specialties and to the fact that it can be asymptomatic.1 The etiology of LS is uncertain although there is evidence for linkages between autoimmune mechanisms and the pathogenesis of LS.5 LS is a scarring process and may cause loss of the labia minora, sealing of the clitoral hood, and burying of the clitoris. In women, vulvar LS can present with progressive pruritus, dyspareunia, dysuria, or genital bleeding.2 These symptoms may also occur in postmenopausal women due to the lack of estrogen in the vaginal area. LS has a considerable impact on affected patients physically, emotionally,
and psychologically, affecting their quality of life through pain and embarrassment and having a significant impact on their sexual lives, which can affect their intimate relationships.

Severe introital stenosis (ie, narrowing of the vaginal opening) occurs rarely. LS can also be associated with squamous cell carcinoma (SCC); there is a 4% lifetime risk of developing SCC among LS sufferers. Histopathological examination of vulval SCC cases shows that over 60% have a background of LS. In the presence of typical clinical features, confirmation with colposcopy and exclusion of conditions such as vulvar intraepithelial neoplasia, a biopsy is not always necessary for the diagnosis of LS. However, histological examination is recommended given the presentation of atypical features and mandatory if the disease fails to respond to treatment and second-line therapy is to be used.

There is no current cure for LS nor is there a comprehensive treatment to cover all patients. Much of the management of LS is aimed at controlling symptoms, such as pruritus in extragenital LS. Current guidelines aim at treating patients with ultrapotent topical corticosteroids, which are symptomatically effective in 90% of women and show variable objective improvement. Corticosteroids require continuous administration and present complications. Furthermore, for the 40% to 57% of postmenopausal women experiencing symptoms resulting from atrophic vaginitis due to menopausal estrogen deficiency and natural aging of the vagina, corticosteroids can worsen the atrophy. As most patients with LS are of postmenopausal age, corticosteroids are a problematic treatment option.

In Australia, the guidelines for treatment of LS are for betamethasone dipropionate ointment (0.05%) to be used twice daily for 1 month, then daily for 2 months, and gradually reduced as needed (ideally 1–2 times per week). This high-maintenance treatment regime can lead to relapse by patients who are not compliant or who find it to be a difficult regime to uphold. A study by Renaud-Vilmer et al investigated remission and recurrence rates of 85 patients with 0.05% clobetasol propionate ointment and found that 72% of women under age 50 showed complete remission, 23% of women between 50 and 70 years old had complete remission, and no women over 70 years old had complete remission. These results highlight the impact of age on the success of topical corticosteroids as treatment for LS.

A variety of other treatment options are available, including calcipotriol, retinoids, systemic steroids, tacrolimus, and pimecrolimus. Photodynamic therapy has also been demonstrated to be beneficial in LS sufferers. Histopathological examination of vulval SCC cases shows that over 60% have a background of LS. In the presence of typical clinical features, confirmation with colposcopy and exclusion of conditions such as vulvar intraepithelial neoplasia, a biopsy is not always necessary for the diagnosis of LS. However, histological examination is recommended given the presentation of atypical features and mandatory if the disease fails to respond to treatment and second-line therapy is to be used. One study investigated a new regenerative approach based on grafting of adipose-derived stem cells and injection of PRP that removed symptoms and reduced atrophy and sclerosus in 15 female patients with a histologic diagnosis of LS who were unresponsive to topical steroid therapy. However, the need for all patients to undergo liposuction to isolate the adipose-derived stem cells means that the process still requires day surgery, thereby having a significant impact on the health system and patients’ lifestyles.

The aim of this study was to investigate the efficacy of injecting PRP alone as a treatment for LS, so that the need for surgery may be eliminated or rendered as minimally invasive as possible for patients who do not respond to topical steroid treatment.

The potential adoption of PRP for autoimmune skin conditions such as LS has been discussed in the literature. However, it still remains unclear whether PRP is a sufficiently effective treatment to replace topical steroids. The aim of this article is to present a new regenerative approach that removes symptoms and reduces atrophy and sclerosus in patients diagnosed with LS. This method is based on injection of PRP.

PATIENTS AND METHODS

Patients were 28 women aged 22 to 88 years (M = 60) who attended FBW Gynaecology Plus from 2013 to 2016 (Table 1). Twenty-six of the 28 patients had confirmed LS on biopsy, with histopathological data indicating possible LS for 1 patient and no LS for one other patient. However, colposcopic examination suggested the presence of LS in all patients. Symptoms were unresponsive to topical steroid treatment in all cases. Those patients who had been using steroids for management of LS symptoms discontinued their use throughout the duration of the study.

After providing written informed consent, patients’ own blood (10mL) was centrifuged (Regens Lab, New York, N.Y.) on site and injected under local anesthesia (lidocaine, 23%; tetracaine, 7%) to any affected areas of the external genitalia, including the labia majora, labia minora,
clitoris, and clitoral hood. The injection was carried out using a 27-gauge needle in a fanning motion to break the scar and fibrotic tissue and retrograde injection of PRP in the tissue. Patients received 3 PRP treatments 4 to 6 weeks apart and again at 12 months. Patients were verbally interviewed about their symptoms (e.g., soreness, discomfort, and dyspareunia) after each treatment session, and lesions were evaluated at each session by colposcopy. Patients with vulval intraepithelial neoplasia (n = 2) were excluded from the study. Posttreatment pain scores were measured after each treatment using a verbal scale from 0 to 10. Patients were asked to complete the Australian Pelvic Floor Questionnaire 24 at baseline and at 2 to 3 months after the final PRP treatment, with higher scores indicating greater frequency of symptoms on each variable. The questionnaire was used to assess symptoms of urinary incontinence, general bladder function, prolapse, and sexual function.

Statistical Analyses

Changes in lesion size, symptoms, and need for topical steroid use were compared from pre- to posttreatment using the Wilcoxon signed-rank test. Statistical analyses were performed using SPSS Statistics version 21.0 (IBM, Chicago, Ill.), and values of \( P \) less than 0.05 were considered to be statistically significant.

RESULTS

Nearly all patients exhibited clinical improvement in the size of their lesions (Table 2), and in 8 of the 28 patients (28.6%), lesions disappeared completely after treatment with PRP. A Wilcoxon signed-rank test indicated that there was a statistically significant decrease in the number of patients with lesions after PRP treatment (\( Z = -4.562; P < 0.001 \)).

Pretreatment symptoms included severe itch (requiring steroid treatment), soreness, discomfort, and/or dyspareunia. As shown in Table 2, more than half the sample had become free of symptoms after the final PRP treatment at 12 months or more. A Wilcoxon signed-rank test showed a statistically significant decrease in the presence of symptoms after treatment (\( Z = -4.768; P < 0.001 \)).

After the final treatment (at 12 months or more), 82.1% of patients (n = 23) no longer needed to use steroids; the remaining 17.9% (n = 5) continued to use them intermittently. A Wilcoxon signed-rank test showed a statistically significant decrease in steroid use after treatment with PRP (\( Z = -4.963; P < 0.001 \)).

Although there was a generally declining trend for responses to items on the Australian Pelvic Floor Questionnaire from pre- to posttreatment, none of the changes were statistically significant, likely due to the very small sample size for pelvic floor disorders.

Patients reported minimal to moderate pain. During the 24 hours after the procedure, 26 patients (92.9%) reported pain scores of 2 to 3; the remaining patients reported scores of 5 and 7, respectively. There were 0 cases of infection, bleeding, hematoma, or other adverse outcomes.

DISCUSSION

In this study, we found that the majority of patients with LS reported significant improvement in their symptoms, with no need for further steroid therapy after PRP treatment. Furthermore, the majority of patients’ lesions disappeared or became smaller after treatment. Based on these limited findings, we hypothesize that PRP can be used as a possible alternative to topical corticosteroids for the treatment of LS or at least in cases where steroids have ceased to work. The PRP procedure is minimally invasive and safe and can be performed in an office setting under local anesthesia. Our findings lend support to those of Casabona et al17 by demonstrating that PRP injection may be an effective treatment for LS, without the need for further surgery and associated risks.

The study possessed several limitations. First, our sample size was limited, and a subsequent pilot study or randomized controlled trial (RCT) with a larger sample size is required to further evaluate the efficacy of PRP. Second, the vast majority of patients were postmenopausal, making it difficult to generalize the current findings to women of reproductive age. However, it should be considered that LS occurs most frequently in postmenopausal women.25 Finally, it is conceivable that the observed improvements in LS symptoms after PRP treatment were partially or wholly due to the tissue needling involved in the PRP injection process rather than to a simple effect of the PRP in and of itself. Subjecting tissues to microtrauma can instigate the tissue repair cascade, and in the present circumstances, this cannot be ruled out as a therapeutic mechanism. For this reason, we intend to conduct a double-blind RCT in which one group is randomized to a saline injection, with a second group randomized to PRP treatment.

CONCLUSIONS

Growth factors released by platelets, monocytes, and nutrients have an important role in phagocytosis of fibrotic tissue, inflammation reduction, angiogenesis stimula-
tion, and collagen III synthesis. The injection of PRP can therefore be considered effective therapy for LS.

It remains unclear whether needleling with saline can result in the same outcome as PRP due to the breakdown of sclerotic tissue, allowing the local stem cells and monocytes to improve tissue healing. There is a need for further RCTs to compare outcomes between these 2 treatment methods and to elucidate the precise mechanism whereby PRP treatment seems to benefit patients with skin conditions like LS.

References

1. Neill SM, Lewis FM, Tatnall FM, et al. Guideline for the management of lichen sclerosus 2010. Br J Dermatol. 2010;163:672–682.
2. Newman N, Dolphin NN, Newman GR. Signs and symptoms of genital lichen sclerosus in women seeking autologous adipose derived stem cell treatment. Med J Obstet Gynaecol. 2015;3:1067–1072.
3. Ball SB, Wojnarowska F. Vulvar dermatoses: lichen sclerosus, lichen planus, and vulval dermatitis/lichen simplex chronicus. Semin Cutan Med Surg. 1998;17:182–188.
4. Meffert J. Lichen sclerosus et atrophicus [Internet]. Medscape. Accessed May 21, 2016. Available at: http://emedicine.medscape.com/article/1123316-overview.
5. Boero V, Brambilla M, Sipio E, et al. Vulvar lichen sclerosus: a new regenerative approach through fat grafting. Gynecol Oncol. 2015;139:471–475.
6. Wallace HJ. Lichen sclerosus et atrophicus. Trans St Johns Hosp Dermatol Soc. 1971;57:9–30.
7. Neill SM, Tatnall FM, Cox NH; British Association of Dermatologists. Guidelines for the management of lichen sclerosus. Br J Dermatol. 2002;147:640–649.
8. Royal College of Obstetricians and Gynaecologists. The Management of Vulval Skin Disorders. Royal College of Obstetricians and Gynaecologists: London. 2011.
9. Sinha P, Sorinola O, Luesley DM. Lichen sclerosus of the vulva. Long-term steroid maintenance therapy. J Reprod Med. 1999;44:621–624.
10. Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9:30.
11. Palacios S. Managing urogenital atrophy. Maturitas. 2009;63:315–318.
12. Fischer G. Treatment of vaginitis and vulvitis. Aust Prescr. 2001;24:59–61.
13. Moyal-Barracco M, Wendling J. Vulvar dermatosis. Best Pract Res Clin Obstet Gynaecol. 2014;28:946–958.
14. Welsh BM, Berzins KN, Cook KA, et al. Management of common vulval conditions. Med J Aust. 2003;178:391–395.
15. Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, et al. Vulvar lichen sclerosus: effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol. 2004;140:709–712.
16. Olejek A, Kozak-Darmas I, Kellas-Slezcka S, et al. Effectiveness of photodynamic therapy in the treatment of lichen sclerosus: cell changes in immunohistochemistry. Neuro Endocrinol Lett. 2009;30:547–551.
17. Casabona F, Priano V, Vallerino V, et al. New surgical approach to lichen sclerosus of the vulva: the role of adipose-derived mesenchymal cells and platelet-rich plasma in tissue regeneration. Plast Reconstr Surg. 2010;126:210e–211e.
18. Jeon YR, Kang EH, Yang CE, et al. The effect of platelet-rich plasma on composite graft survival. Plast Reconstr Surg. 2014;134:239–246.
19. Salcido RS. Autologous platelet-rich plasma in chronic wounds. Adv Skin Wound Care. 2013;26:248.
20. Harris NL, Huffer WE, von Stade E, et al. The effect of platelet-rich plasma on normal soft tissues in the rabbit. J Bone Joint Surg Am. 2012;94:786–793.
21. Nofal E, Helmy A, Nofal A, et al. Platelet-rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. Dermatol Surg. 2014;40:864–873.
22. Dionysiou D, Demiri E, Foroglou P, et al. The effectiveness of intralesional injection of platelet-rich plasma in accelerating the healing of chronic ulcers: an experimental and clinical study. Int Wound J. 2013;10:397–406.
23. Jeong KH, Shin MK, Kim NI. Refractory lipodermatosclerosis treated with intralesional platelet-rich plasma. J Am Acad Dermatol. 2011;65:e157–e158.
24. Baessler K, O’Neill SM, Maher CF, Battistutta D. Australian pelvic floor questionnaire: a validated interviewer-administered pelvic floor questionnaire for routine clinic and research. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:149–158.
25. O’Connell TX, Nathan LS, Satmary WA, et al. Nonneoplastic epithelial disorders of the vulva. Am Fam Physician. 2008;77:321–326.